Oncology Medications

ALUNBRIG®
(brigatinib)

Alunbrig (brigatinib) now available from Onco360!

ALUNBRIG® is a kinase inhibitor indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test.

Dosage and Administration

The recommended dosage for ALUNBRIG is 90 mg orally once daily for the first 7 days; then increase to 180 mg orally once daily. May be taken with or without food.

Dosage Forms and Strengths

 

For more information, visit Alunbrig.com 

How to Refer

Limited Distribution Oncology Medications

e-Prescribe

Oncomed Dba Onco360 or
NPI# 1679618151

VONJO™ (pacritinib) for Myelofibrosis

Fax

877.662.6355

Order Forms